HOME >> MEDICINE >> NEWS
Other highlights in the Dec. 6 JNCI

r patients treated with two chemotherapy regimens, the high-dose CTC (cyclophosphamide, thiotepa, and carboplatin) regimen and the conventional FEC (5-fluorouracil, epirubicin, and cyclophosphamide) regimen, as well as patients who hadn't received chemotherapy and healthy women without cancer. The patients were given neuropsychological testing before and 6 months after treatment, control subjects underwent repeated testing with a 6-month interval.

The authors found that patients taking the CTC regimen exhibited a deterioration in cognitive performance over time. They suggest that some chemotherapy regimens for breast cancer affect cognition in a subset of women.

Contact: Ramona Pauwels, 31-20-512-2850, r.pauwels@nki.nl


Genetic Variant Linked to Drug-Induced Diarrhea

Patients with a common genetic variant have an increased risk of diarrhea when treated with a common cancer drug, a new study shows.

Gefitinib, which is commonly used to treat non-small-cell lung cancer, has common side-effects that include diarrhea and skin toxicity. Sharyn D. Baker, Pharm.D., Ph.D., of the St. Jude's Children's Research Hospital in Memphis, Tenn., and colleagues examined the association between variant forms of ABCG2, a protein that acts on gefitinib, and diarrhea.

They found that a common variant of the ABCG2 gene was associated with diarrhea. Seven of 16 patients with the variant had diarrhea when taking gefitinib compared with 13 of 108 patients without the variant.

Contact: Bonnie Kourvelas, 901-495-4815, media@stjude.org


Protein Linked to Poor Prognosis in Some Breast Cancer Patients

Low expression of a protein called p27kip1 was associated with low breast cancer survival and higher relapse rates, according to a new study.

Peggy L. Porter, M.D., of the Fred Hutchinson Cancer Research C
'"/>

Contact: Andrea Widener
jncimedia@oxfordjournals.org
301-841-1286
Journal of the National Cancer Institute
5-Dec-2006


Page: 1 2 3 4

Related medicine news :

1. Other highlights in the May 2 JNCI
2. Other illnesses play role in difference in breast cancer survival rates between blacks and whites
3. Other highlights in the October 5 JNCI
4. Other highlights in the July 20 JNCI
5. Other highlights in the May 18 JNCI
6. Other highlights in the May 4 JNCI
7. Research highlights from Thoracic Society Conference
8. SCAI highlights study using wireless technology to speed care of heart attack patients
9. SCAI Founders Lecture highlights remarkable progress in catheter-based aortic valve replacement
10. Latest IPCC report highlights need for integrated climate/human behavior models
11. New report highlights aromatase inhibitor side effects

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
(Date:9/9/2017)... NEW YORK , Sept. 8, 2017 ... largest independent supplier of medical equipment, supplies, drugs, ... that it has entered into an agreement to acquire ... surgical equipment based in Holtsville, New York ... which specializes in supplying new and emerging medical practices, ...
Breaking Medicine Technology:
Cached News: